Technology GramEye, a medical startup aiming to address AMR, raises ¥570 million in Series B funding.
GramEye, a Japanese medical startup addressing antimicrobial resistance (AMR), has raised ¥570 million in Series B funding to expand its AI-driven infectious disease diagnostics, enhance its flagship Mycrium system, and pursue FDA approval for global deployment.
